Wall Street’s Shock Reversal on Immutep: Analysts Who Set $12.00 Price Targets Stripped Their Ratings After TACTI-004’s Sudden Collapse Cost IMMP Investors $2.28 Per Share
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NEW YORK, May 13, 2026 — Levi & Korsinsky, LLP tracks the evolution of Wall Street analyst opinion on Immutep Limited (NASDAQ: IMMP) in connection with a pending securities class action. Investors who purchased IMMP ADRs between March 24, 2025 and March 12, 2026 and suffered losses may be entitled to compensation. Find out if you are eligible to recover your analyst-misled losses or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Jefferies downgraded Immutep Limited (NASDAQ: IMMP) to Hold, calling the TACTI-004 discontinuation “a very surprising outcome.” Baird slashed its price target from $7.00 to $1.00. Maxim Group removed its $12.00 target entirely. In a single trading session, the analyst consensus on IMMP shifted from optimism to abandonment, and shareholders lost approximately 83% of their investment.
IMMP shares fell from $2.76 to $0.48 on March 13, 2026, a loss of $2.28 per share (approximately 83%), after the company disclosed that an Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial for futility. The lead plaintiff deadline is July 6, 2026.
Initial Analyst Optimism Built on Company Representations
Throughout the Class Period, multiple sell-side firms maintained bullish ratings on IMMP. Maxim Group carried a $12.00 price target. Baird set a $7.00 target. These valuations were constructed on the premise that TACTI-004 would succeed, a premise the lawsuit contends was supported by statements from Immutep that allegedly concealed material risks to the trial’s viability.
The Downgrades Begin: March 13, 2026
The corrective disclosure triggered a wave of analyst reversals:
● Jefferies downgraded IMMP to Hold, stating the outcome was “very surprising” given previous efficacy and safety readouts
● Baird Equity downgraded to Neutral and cut its price target by 86%, from $7.00 to $1.00, noting it did “not see a clear path forward for efti”
● Citizens downgraded to Market Perform, observing that “very few studies fail at the futility analysis level” and questioning whether efti’s mechanism of action would now be “called into question”
● Maxim Group downgraded to Hold and removed its $12.00 target entirely, citing “significant lack of clarity on the path forward” and “potential negative read-through across the pipeline”
Execution Concerns Replace Confidence on Wall Street
Baird acknowledged the result was a surprise because “prior efti/pembro/chemo data had shown numerically higher ORR, OS, and PFS vs. pembro + chemo alone regardless of PD(L)-1 expression levels.” Maxim noted the Phase III study “was the primary value driver” and its failure left “limited visibility on next steps.” The securities action contends these analysts built their models on company disclosures that omitted material internal data signaling futility risk.
Why Analyst Shifts Matter for Investors
The unanimity and severity of these downgrades reflect the degree to which the investing public relied on Immutep’s statements. As alleged, analysts and investors were pricing IMMP based on representations that the trial exhibited “strong operational progress” and was “on track for key milestones.” The complaint charges that internal data available to defendants told a different story.
“When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. The breadth of downgrades on IMMP following the TACTI-004 discontinuation underscores how deeply the market had relied on the company’s characterizations of the trial’s trajectory.” — Joseph E. Levi, Esq.
Speak with an attorney about recovering your IMMP investment losses or call (212) 363-7500.
LEAD PLAINTIFF DEADLINE: July 6, 2026
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP, Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered for investors.
Frequently Asked Questions About the IMMP Lawsuit
Q: How much did IMMP stock drop? A: Shares fell approximately 83%, a decline of $2.28 per share, after Immutep disclosed that the Independent Data Monitoring Committee recommended discontinuing the TACTI-004 Phase III trial for futility. Investors who purchased shares during the Class Period at artificially inflated prices may be entitled to compensation.
Q: When did Immutep allegedly mislead investors? A: The Class Period runs from March 24, 2025 to March 12, 2026. The alleged fraud was revealed through the March 13, 2026 corrective disclosure announcing the trial’s discontinuation, causing the significant stock decline.
Q: What do IMMP investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What if I already sold my IMMP shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the Class Period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
Tel: (212) 363-7500
Fax: (212) 363-7171